Search
Close this search box.

Category

Category

EZVIZ breaks new ground in outdoor security with the 4G & Wi-Fi battery camera family, addressing everyday challenges while inspiring new scenarios from homes to wilderness

EZVIZ 4G & Wi-Fi Battery Camera Family Hot Debut EZVIZ launches the groundbreaking 4G & Wi-Fi Battery Camera Family, embedded with advanced wild animal detection, 4G & Wi-Fi auto-switching, and new AOV technology, smashing the pain points of battery camera usage. JOHANNESBURG, Feb. 02, 2026 (GLOBE NEWSWIRE) — EZVIZ, recognized

EZVIZ breaks new ground in outdoor security with the 4G & Wi-Fi battery camera family, addressing everyday challenges while inspiring new scenarios from homes to wilderness

EZVIZ 4G & Wi-Fi Battery Camera Family Hot Debut EZVIZ launches the groundbreaking 4G & Wi-Fi Battery Camera Family, embedded with advanced wild animal detection, 4G & Wi-Fi auto-switching, and new AOV technology, smashing the pain points of battery camera usage. JOHANNESBURG, Feb. 02, 2026 (GLOBE NEWSWIRE) — EZVIZ, recognized

Details on the timetable of the simplified tender offer on North Atlantic Energies shares

Paris, Jan. 30, 2026 (GLOBE NEWSWIRE) — NORTH ATLANTIC ENERGIES Details on the timetable of the simplified tender offer on North Atlantic Energies shares Paris, FRANCE – January 30, 2026 – North Atlantic France SAS (“North Atlantic France”) refers to its acquisition from ExxonMobil France Holding SAS (“ExxonMobil”) of ExxonMobil’s

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD). Regulatory submission

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD). Regulatory submission